GS

Gorla Srinivasa Reddy

Director DIN 00734320
DIN 00734320 First appointment Dec 2005
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Dec 2005
Shareholding value β€’β€’β€’β€’ Premium profile

About Gorla Srinivasa Reddy

Data last updated:

Gorla Srinivasa Reddy was a Director at Sunivo Life Sciences Private Limited (from 2009) and Director at Nucleus Drugs Private Limited (from 2005).

DIN 00734320
First Appointment 21 Dec 2005
Oldest Company Age 20 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sunivo Life Sciences Private Limited U24297TG2009PTC063645
Director12 May 20092009Strike Off
Nucleus Drugs Private Limited U24230TG2005PTC048507
Director21 Dec 20052005Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Sunivo Life Sciences Private Limited
Nucleus Drugs Private Limited
Premium access

Shareholding and investment profile for Gorla Srinivasa Reddy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gorla Srinivasa Reddy

Gorla Srinivasa Reddy was first appointed on 21 Dec 2005 as Director at Nucleus Drugs Private Limited. The most recent appointment on record is 12 May 2009 at Sunivo Life Sciences Private Limited.

Gorla Srinivasa Reddy held 2 earlier board appointments: Sunivo Life Sciences Private Limited (Director, from 12 May 2009); Nucleus Drugs Private Limited (Director, from 21 Dec 2005).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available